From a McMaster metabolomics lab to a precision autoimmune platform.
Origins
Technology developed through Prof. Philip Britz-McKibbin's metabolomics research program at McMaster University, supported by issued intellectual property and peer-reviewed research.
Platform
MetaboType formed to translate this analytical capability into a longitudinal measurement platform for autoimmune disease.
Focus
Making autoimmune disease measurable, predictable and actionable — beginning with lupus.
Team
Louis Hui
CEO
Louis is building MetaboType because autoimmune disease needs better tools between clinic visits. His focus is turning the science into a company that can give patients, clinicians and partners better visibility into changing disease biology — starting with lupus.
Dr. Philip Britz-McKibbin
CSO
Phil has spent years developing the metabolomics technology that makes MetaboType possible. For him, MetaboType is the opportunity to translate that science into something more meaningful: a platform that can help make complex disease more measurable, individualized and ultimately more predictable.
Richard Hui
Chief AI Officer
Richard is focused on turning longitudinal biological data into useful intelligence. His goal is to build the computational layer that can recognize patterns across time, learn from individual patient trajectories, and help transform metabolomic measurements into practical insight for autoimmune disease.